Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M75.8Revenue $M0.2Net Margin (%)-5,731.9Z-Score-14.8
Enterprise Value $M65.4EPS $-0.7Operating Margin %-12,417.5F-Score3
P/E(ttm))0Cash Flow Per Share $-0.1Pre-tax Margin (%)-5,731.9Higher ROA y-yN
Price/Book8.910-y EBITDA Growth Rate %0Quick Ratio3.7Cash flow > EarningsY
Price/Sales1545-y EBITDA Growth Rate %0Current Ratio4.2Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-84.6Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-136.9Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M65.9ROI % (ttm)-121.7Gross Margin Increase y-yN

Gurus Latest Trades with CVM

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found!

CVM is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


CVM: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
KERSTEN GEERT RCEO 2013-12-30Buy300,000$0.691.67 view
KERSTEN GEERT RChief Executive 2013-10-09Buy8,400$0.7945.57 view
YOUNG PETER RDirector 2013-06-19Buy25,000$0.24379.17 view
KERSTEN GEERT RChief Executive 2013-06-14Buy145,120$0.24379.17 view
KERSTEN GEERT RCEO 2013-05-20Buy40,000$0.25360 view
KERSTEN GEERT RCEO 2013-05-02Buy118,700$0.27325.93 view
PRICHEP PATRICIA BSenior Vice President 2013-03-27Buy25,000$0.22422.73 view
YOUNG PETER RDirector 2013-03-27Buy25,000$0.23400 view
KERSTEN GEERT RCEO 2013-03-26Buy348,125$0.21447.62 view
DE CLARA MAXIMILIANPresident 2011-03-07Sell100,000$0.6188.52 view

Press Releases about CVM :

    Quarterly/Annual Reports about CVM:

    News about CVM:

    Articles On GuruFocus.com
    CELSCISci Corp Reports Operating Results (10-Q) Feb 09 2011 
    CELSCISci Corp Reports Operating Results (10-Q) Aug 16 2010 
    CELSCISci Corp Reports Operating Results (10-Q) May 17 2010 
    CELSCISci Corp Reports Operating Results (10-Q) Feb 12 2010 
    CELSCISci Corp Reports Operating Results (10-Q/A) Feb 01 2010 
    CELSCISci Corp Reports Operating Results (10-Q/A) Feb 01 2010 
    CELSCISci Corp Reports Operating Results (10-Q/A) Jan 29 2010 
    CELSCISci Corp Reports Operating Results (10-K) Jan 13 2010 
    CELSCISci Corp Reports Operating Results (10-Q) Aug 14 2009 
    CELSCISci Corp Reports Operating Results (10-Q) Aug 14 2009 

    More From Other Websites
    NEW STORY France Becomes 17th Country to Clear CEL-SCI for Patient Enrollment in Its Global Phase... Jul 30 2014
    8:31 am CEL-SCI Corp: France becomes 17th country to clear CEL-SCI for patient enrollment in its... Jul 30 2014
    France Becomes 17th Country to Clear CEL-SCI for Patient Enrollment in Its Global Phase III Head and... Jul 30 2014
    CEL SCI CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jul 23 2014
    CEL-SCI Has Been Cleared to Begin Patient Enrollment Jul 23 2014
    NEW STORY CEL-SCI Receives Regulatory Clearance to Expand Phase III Head and Neck Cancer Trial into... Jul 22 2014
    CEL-SCI Receives Regulatory Clearance to Expand Phase III Head and Neck Cancer Trial into Turkey Jul 22 2014
    NEW STORY CEL-SCI Expands Its Phase III Head and Neck Cancer Trial into Sri Lanka Jul 21 2014
    CEL-SCI Expands Its Phase III Head and Neck Cancer Trial into Sri Lanka Jul 17 2014
    CEL-SCI Expands Its Phase III Head and Neck Cancer Trial into Sri Lanka Jul 17 2014
    NEW STORY CEL-SCI Receives $225,000 NIH Research Grant to Develop Rheumatoid Arthritis Treatment Jul 15 2014
    CEL-SCI Receives $225,000 NIH Research Grant to Develop Rheumatoid Arthritis Treatment Jul 15 2014
    NEW STORY CEL-SCI Presents Rheumatoid Arthritis Data at the 12th Vaccines Research & Development:... Jul 11 2014
    CEL-SCI Presents Rheumatoid Arthritis Data at the 12th Vaccines Research & Development: All Things... Jul 11 2014
    NEW STORY CEL-SCI Receives Regulatory Clearance to Expand CEL-SCI'S Phase III Head and Neck Cancer... Jul 08 2014
    CEL-SCI Receives Regulatory Clearance to Expand CEL-SCI’S Phase III Head and Neck Cancer Trial... Jul 08 2014
    NEW STORY CEL-SCI Reports 93% Increase in Sequential Quarterly Patient Enrollment in Its Phase III... Jul 02 2014
    CEL-SCI Reports Continued Increase in Sequential Quarterly Patient Enrollment in Its Phase III Head... Jun 03 2014
    CEL-SCI receives approval to expand Phase III trial to U.K. Jun 02 2014
    CEL-SCI Receives Approval to Expand Its Immunotherapy Phase III Head and Neck Cancer Trial into the... Jun 02 2014

    Add Notes, Comments or Ask Questions

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK
    Email Hide